Pascal Biosciences is a company that focuses on diseases such as glioblastoma and other intractable cancers. It develops cannabinoid-based small molecules and immuno-stimulatory molecules designed to enhance the efficacy of checkpoint inhibitors. In addition, the company works on a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.